Newer anticonvulsants: Comparative review of drug interactions and adverse effects

Drugs

Volumn 60, Issue 1, 2000, Pages 23-33

  Sabers, A ^a   Gram, L ^a  

^a Dianalund Epilepsy Hospital   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CALCIUM ANTAGONIST; CARBAMAZEPINE; CYTOCHROME P450 3A; ENZYME INDUCING AGENT; FELBAMATE; GABAPENTIN; LAMOTRIGINE; LIVER ENZYME; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; SEROTONIN UPTAKE INHIBITOR; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

BIRTH DEFECT; DRUG ANTAGONISM; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG TOLERABILITY; ELDERLY CARE; HUMAN; MENTAL DEFICIENCY; MENTAL DISEASE; REVIEW; SEIZURE; TREATMENT OUTCOME; VASCULAR DISEASE;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0033907007     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200060010-00003     Document Type: Review

References (133)

1. Vigabatrin for refractory complex partial seizures: Multicenter single-blind study with long-term follow up
2. Lamotrigine, a new anticonvulsant: Pharmacokinetics in normal humans.
3. Effect of maalox TC® on single-dose pharmacokinetics of gabapentin capsules in healthy subjects
4. Adjunctive treatment of partial seizures with tiagabine: A placebo-controlled trial
5. Oxcarbazepine and oral contraceptives
6. Effect of topiramate on the pharmacokinetics of oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy
7. An overview of the efficacy and tolerability of new antiepileptic drugs
8. The new antiepileptic drugs: A systematic review of their efficacy and tolerability
9. Oxcarbazepine (GP 47.680): A possible alternative to carbamazepine
10. Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: Results of a retrospective study
11. Drug-drug interaction profile of oxcarbazepine in children and adults
12. Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine
13. Possible interaction between oxcarbazepine and an oral contraceptive
14. Comparison of oxcarbazepine and carbamazepine: A double-blind study
15. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy
16. Survey of 260 epileptic patients treated with oxcarbazepine (Trileptal®) on a named-patient basis
17. Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: One year follow-up
18. Cognitive function and anticonvulsant therapy: Effect of monotherapy in epilepsy
19. Oxcarbazepine-induced hyponatremia, a cross-sectional study
20. Hyponatremia during oxcarbazepine therapy
21. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment
22. Hyponatremia induced by oxcarbazepine
23. Basic haematological parameters, serum gamma-glutamyl-transferase activity, and erythrocyte folate and serum vitamin B12 levels during carbamazepine and oxcarbazepine therapy
24. Interaction between vigabatrin and phenytoin
25. Long-term study of gamma-vinyl GABA in the treatment of epilepsy
26. Efficacy and safety of vigabatrin in the long-term treatment of refractory epilepsy
27. Vigabatrin in the treatment of epilepsy: A long-term follow-up study
28. Evaluation of vigabatrin as an add-on drug in the management of severe epilepsy
29. Gamma-vinyl GABA (vigabatrin) and mood disturbances
30. Vigabatrin and depression
31. Vigabatrin and psychosis
32. Vigabatrin and behaviour disorders: A retrospective survey
33. Vigabatrin and behaviour disturbances
34. Vigabatrin and psychosis
35. Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy
36. Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy
37. Influence of vigabatrin on cognitive performances and behaviour in patients with drug-resistant epilepsy
38. Development of myoclonus in patients with partial epilepsy during treatment with vigabatrin: An electroencephalographic study
39. Reversible motor disturbances induced by vigabatrin
40. Severe persistent visual field constrictions associated with vigabatrin
41. Vigabatrin, a gabaergic antiepileptic drug causes concentric visual fields defects
42. Characteristics of unique visual field defect attributed to vigabatrin
43. Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication
44. Outer retinal dysfunction in patients treated with vigabatrin
45. A controlled study of vigabatrin and visual abnormalities
46. Severe persistent visual field constriction associated with vigabatrin: Reaction might be dose dependent
47. Reversibility of vigabatrin-induced visual field defects
48. Acute effect of lamotrigine (BW430C) in persons with epilepsy
49. Lamotrigine: Single dose pharmacokinetics, and initial one week experience in refractory seizures
50. Sodium valproate acutely inhibits lamotrigine metabolism
51. Lamotrigine pharmacokinetics in patients receiving felbamate
52. Clinical pharmacology of lamotrigine
53. Effect of lamotrigine on the pharmacology of the combined oral contraceptive pill
54. Lamotrigine induced carbamazepine toxicity: An interaction with carbamazepine-10, 11-epoxide
55. No effect of LTG on CBZ and CBZ-E concentrations
56. Effect of lamotrigine on carbamazepine epoxide/carbamazepine serum concentration ratios in adult patients with epilepsy
57. Carbamazepine toxicity with lamotrigine: Pharmacokinetic or pharmacodynamic interaction
58. Lamotrigine toxicity secondary to sertraline
59. Safety review of adult clinical trial experience with lamotrigine
60. Lamortigine associated with insomnia
61. Lamotrigine-induced severe cutaneous adverse reactions
62. Lamotrigine-associated rash: Risk/benefit considerations in adults and children
63. Leucopenia associated with lamotrigine
64. Agranulocytosis associated with lamotrigine
65. Fulminant hepatic failure induced by lamotrigine
66. Multisystem adverse reaction to lamotrigine
67. Outcomes of add-on treatment with lamotrigine in partial epilepsy
68. Human safety of lamotrigine
69. Gabapentin as add-on therapy in refractory partial epilepsy: A double-blind, placebo-controlled, parallel-group study
70. The long-term safety and efficacy of gabapentin (Neurontin®) as add-on therapy in drug resistant partial epilepsy
71. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: A double-blind, placebo-controlled study
72. Clinical efficacy and safety of gabapentin
73. Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures
74. A double-blind trial of gabapentin monotherapy for newly diagnosed partial epilepsy
75. Weight gain associated with the use of gabapentin
76. Conversion to high dose gabapentin monotherapy in patients with medically refractory partial epilepsy
77. Exacerbation of seizures in Lennox-Gastaut syndrome by gabapentin
78. Gabapentin-associated myoclonus
79. Gabapentin-related myoclonus
80. Choreoathetosis as a side effect of gabapentin therapy in severely neurologically impaired patients
81. Gabapentin and cognition: A double blind, dose ranging, placebo controlled study in refractory epilepsy
82. Cognitive abilities and adjustment with gabapentin: Results of a multisite study
83. Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing anti-epileptic drugs
84. Population analysis of the pharmacokinetics of tiagabine in patients with epilepsy
85. Open label dosage and tolerability study of tiagabine monotherapy in patients with refractory complex partial seizures
86. A double-blind, placebo-controlled trial of tiagabine given three-times daily as add-on therapy for refractory partial seizures
87. Tiagabine therapy for complex partial seizures
88. Nonconvulsive status epilepticus in two patients receiving tiagabine treatment
89. Neuropsychological effects of tiagabine, a potential new antiepileptic drug
90. Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy
91. Effects of tiagabine monotherapy on abilities, adjustment, and mood
92. Absence of concentric visual field defects in patients with initial tiagabine monotherapy
93. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during and concomitant therapy
94. The steady-state (SS) pharmacokinetics (PK) of phenytoin (Dilantin) and topiramate (Topamax®) in epileptic patients on monotherapy and during combination therapy
95. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages
96. Safety of topiramate: Adverse events and relationships to dosing
97. An audit of topiramate use in a general neurology clinic
98. Nephrolithiasis during treatment with topiramate
99. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures
100. Effect of topiramate on attention
101. New antiepileptic drugs: A systematic review of their efficacy and tolerability
102. Discrepancies between meta-analyses and subsequent large randomized, controlled trials
103. The promise and problems of meta-analyses
104. New antiepileptic drugs: The drugs are not all the same
105. New anti-epiletic drugs: Analysis based on number needed to treat shows differences between drugs studied
106. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy
107. Vigabatrin vs carbamazepine monotherapy in newly diagnosed focal epilepsy: A randomized response conditional cross-over study
108. Topiramate monotherapy for partial onset seizures
109. The use of lamotrigine in juvenile myoclonic epilepsy
110. Lamotrigine use in twelve patients with the Lennox-Gastaut syndrome
111. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome
112. Lamotrigine as add-on drug in typical absences
113. Lamictal (lamotrigine) monotherapy for typical absence seizures in children
114. A randomized double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy
115. Aggravation of severe myoclonic epilepsy of infancy by lamotrigine
116. A randomized, placebo-controlled study of topiramate in primary generalized tonic clonic seizures
117. A double blind, randomized trial of topiramate in Lennox-Gastaut syndrome
118. Multicenter, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy
119. Lack of effect of gabapentin on the pharmacokinetics of a norethindrone acetat/ethinyl estradiol-containing oral contraceptive
120. Fertility in persons with epilepsy: 1935-1974
121. Polycystic ovaries and hyperandrogeism in women taking valproate for epilepsy
122. Replacing valproate with lamotrigine reduces cardiovascular risks and insulin mediated hyperandrogenism in women with epilepsy
123. Serum folic acid levels in epileptic mothers and their relationship to congenital malformations
124. Alteration of embryonic folate metabolism by valproic acid during organogenesis: Implications for mechanism of teratogenesis
125. An assessment of serum and red blood cell folate concentrations in patients with epilepsy on lamotrigine therapy
126. Positive and negative psychotropic effects of lamotrigine in patients with epilepsy and mental retardation
127. Aggressive behaviour in intellectually challenged patients with epilepsy treated with lamotrigine
128. Improved neurological function accompanies effective control of the Lennox-Gastuat syndrome with Lamictal: Results of a multinational, placebo-controlled trial
129. Lamotrigine add-on therapy is associated with improvement in mood in patients with severe epilepsy
130. Lamotrigine in Rett syndrome
131. Behavioral side effects of gabapentin in children
132. Gabapentin associated with aggressive behaviour in pediatric patients with seizures
133. A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities